UC2288

UC2288 is a small molecule attenuator of the cyclin-dependent kinase inhibitor p21 (CDKN1A). Derived from the multi-kinase inhibitor sorafenib, UC2288 was designed to lack sorafenib's inhibitory activity against RAF and VEGFR, instead selectively reducing p21 protein and mRNA levels. It functions independently of p53 and is widely utilized as a research tool to investigate the role of p21 in cell cycle progression, senescence, and apoptosis. Recent research has explored its potential in mitigating aging-associated lymphatic dysfunction and cardiac injury following viral infections by restoring mitochondrial and endoplasmic reticulum density in senescent endothelial cells. It has also been studied in preclinical models of renal cell carcinoma and other cancers.